Ralph J. Riello III, PharmD, BCPS
@ralphadelta
Clinical Pharmacy Specialist, Clinical & Translational Research @YaleMed | Residency @YNHH | PharmD @UConnPharmacy | I fix ๐ with ๐&๐ป| ๐ฅ๐ซ๐
Somehow only now just discovering @ACCP made my BCPS PSAP chapter on HF the one you get as a free sampleโenjoy #TwitteRx #GDMTworks ๐๐ซ accp.com/docs/bookstoreโฆ

Blocking the Commanders' new stadium deal unless they change their name back to the Redskins is like an HOA requiring you to fly the Confederate flag.
WOW! One of the most moving grand rounds I can recall in a very, very long time. โItโa hard for me to even be circumspect about thisโฆโ Far too few recognize the urgency of the current moment for our countryโs already poor CRM health. Inspiring & brilliant talk, @rkwadhera!

๐๐๐
We've updated the big sign at the ballpark, and renewed our commitment to ALL people, EVERYWHERE. This is, and always will be, everyone's ballpark.
You donโt know what you have until itโs gone, Storrs edition:
Happy Monday (a day early!) a new @MJHLifeSciences @Pharmacy_Times Tell-Tale Heart Podcast. Listen as @ralphadelta and I discuss how pharmacist can implement the PROMPT trials in your system! Listen here or where you get your podcast: audioboom.com/posts/8729124-โฆ
very rare to see a head-to-head RCT of two market leading blockbusters, $LLY & $NOVO, specially with 6+ years still left on either GLP1RAโs patent ๐ bold science; bad trade ๐๐
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: @NEJM ๐ฅธ SURMOUNT-5 Trial: Wow! ๐ฑ Summary ๐๐๐
Join us for another PGY2 CE Spotlight! This time we are joined by Yeganeh Haghi, @Yegan_h_ from @BIDMCPharmRes The topic this week is on the role of GLP-1 receptor agonists in cardiovascular-kidney-metabolic health! #CardioCE
As a Giants fan, we gotta take some credit for this Eagles dominance. Youโre not here without the incompetence of OUR front office. #wemissyousaquon
The Interventional Cardiologist arriving for STEMI call.
@yaleHFdoc @nihardesai927 @ralphadelta and colleagues found that only 25% of Medicare Part D plans cover mavacamten, and almost all plans require prior authorizations and high cost-sharing levels. #financialtoxicity #HCM @YaleCardiology pubmed.ncbi.nlm.nih.gov/39817331/
RFK Jr: Screams about dyes in food which ARE regulated for safety and Screams about vaccine ingredients which ARE tested and regulated for safety While consuming a synthetic dye, methylene blue, that is NOT regulated OR tested for safety & encouraging others to do so too. 1/
lower is betterโbut lower *for longer* is best ๐๐ซ
Why waiting to start on a cholesterol-lowering medication until you are older is NOT a good strategy. Start at: Age 60 - 27% reduction in events. Age 50 - 35 reduction in events. Age 30 - 52% reduction in events. And this is with a starting LDL-C of only 3.5 (67).
Mavacamten is covered by 25% Medicare plans, but 94% plans mandate prior auths and most have high out-of-pocket costs @KannuBansalMD @SaurabhSDani @LaheyCardiology @YaleHFdoc @MasriAhmadMD @ralphadelta #AHAJournals ahajrnls.org/4jBNofo
drew lock would be a good bridge quarterback for us next year in the sense that if hes our quarterback next year i will jump off a bridge
Stop by the @Boehringer booth at @ASHPOfficial Midyear in NOLA to meet my hologram! Yesโฆan actual 3D hologram ๐

Again, people donโt realize how bad itโs going to be for an anti-vaxxer conspiracy theorist to be in charge of our nationโs public health.
Congratulations @realDonaldTrump on your historic victory. Letโs bring the country together and Make America Healthy Again!
Obama in 2028 when Trump repeals the 22nd ammendment
๐ค๐ค๐ค๐ฎ๐น๐ @Volpe_Anthony ๐๐ฝ
The Anthony Volpe game
KAMALA WITH THE HAIL MARY??!
everyone realizes the results of the election are dependent on this goal line stand right